Takeda Pharmaceutical Co Ltd ADR (TAK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $68.47B
Last updated: Nov 17, 2026 at 11:06 AM ET
Takeda Pharmaceutical Co Ltd ADR (TAK) Valuation Multiples
Takeda Pharmaceutical Co Ltd ADR (TAK) trades at 2.3x sales and 1.5x book value. Its P/S of 2.3x is above its 5-year median of 1.6x.
Current Multiples
TAK reports in JPY, so earnings multiples appear here only when its per-share earnings can be confirmed. Its free cash flow yield is 4.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 2.3x |
| Price to book | 1.5x |
| EV/EBITDA | 11.5x |
| Price to FCF | 24.5x |
| EV/FCF | 33.8x |
| PEG | N/A |
| FCF yield | 4.1% |
Historical Medians
Against its 10-year medians, its P/S is 35.3% above 1.7x and its P/B is 36.4% above 1.1x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.3x | 1.6x | 1.7x |
| P/B | 1.5x | 1.0x | 1.1x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.4x in 2021 to 2.8x in 2017.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $15.59 | 1.7x | 1.0x |
| 2024 | $13.24 | 1.4x | 0.9x |
| 2023 | $14.27 | 1.5x | 0.9x |
| 2022 | $15.60 | 1.6x | 1.0x |
| 2021 | $13.63 | 1.4x | 0.9x |
| 2020 | $18.20 | 1.9x | 1.3x |
| 2019 | $19.73 | 2.1x | 1.4x |
| 2018 | $16.82 | 1.6x | 1.4x |
| 2017 | $28.45 | 2.8x | 2.4x |
| 2016 | $20.78 | 2.7x | 1.9x |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TAK
Is TAK stock overvalued?
GNG's valuation label for TAK is Overvalued.
What is TAK's price to sales ratio?
Takeda Pharmaceutical Co Ltd ADR has a price to sales ratio of 2.3x.
TAK pages: Overview, Dividends, Financials, Valuation, Competitors